Literature DB >> 10374710

Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo.

E Gur1, E Dremencov, B Lerer, M E Newman.   

Abstract

Venlafaxine is a dual serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline uptake inhibitor which has been claimed to have an onset of antidepressant action which is faster than for other comparable drugs. The effects of venlafaxine on brain 5-HT levels in vivo have not yet been examined. Acute administration of venlafaxine to rats by i.p. injection resulted in dose-dependent increases in cortical and hippocampal 5-HT levels, as measured by in vivo microdialysis, over the range 5-20 mg/kg. The effect of venlafaxine (10 mg/kg i.p.) was potentiated by prior administration of pindolol (10 mg/kg s.c.) in hippocampus but not in frontal cortex. Daily administration of venlafaxine (5 mg/kg i.p.) for 4 weeks did not change basal 5-HT levels in either brain area. The effect of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 0.2 mg/kg s.c.) to reduce 5-HT levels was unaffected by chronic venlafaxine at this dose, indicating that there was no change in sensitivity of presynaptic 5-HT1A autoreceptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374710     DOI: 10.1016/s0014-2999(99)00164-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?

Authors:  G G Kinney; M T Taber; V K Gribkoff
Journal:  Mol Neurobiol       Date:  2000-06       Impact factor: 5.590

2.  Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.

Authors:  Kelly A Warren; Irene C Solomon
Journal:  Respir Physiol Neurobiol       Date:  2012-07-31       Impact factor: 1.931

3.  A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain.

Authors:  X Tong; P N Patsalos
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 4.  Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Authors:  Claire Rampon; Bruno P Guiard; Basile Coutens; Antoine Yrondi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-10       Impact factor: 4.415

5.  Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Authors:  Tracy M Felton; Tommy B Kang; Stephan Hjorth; Sidney B Auerbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

6.  Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey.

Authors:  George M Anderson; Christina S Barr; Stephen Lindell; Amy C Durham; Ilya Shifrovich; J Dee Higley
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

7.  Reduction in the latency of action of antidepressants by 17 beta-estradiol in the forced swimming test.

Authors:  E Estrada-Camarena; N M Vega Rivera; C Berlanga; A Fernández-Guasti
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

8.  Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.

Authors:  D J P David; M Bourin; G Jego; C Przybylski; P Jolliet; A M Gardier
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

9.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.